Lv3
260 积分 2021-08-24 加入
Targeting IL-6 trans-signalling: past, present and future prospects
13天前
已完结
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
15天前
已完结
DOP033 Pre-Clinical Development of SL-325, a High Affinity DR3 Blocking Antibody, for Durable Blockade of the DR3/TL1A Axis in Inflammatory Bowel Disease
22天前
已关闭
Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling
23天前
已完结
P1114 Engineering and Development of a Novel Bispecific Antibody Targeting IL-23 and TL1A
1个月前
已关闭
Trends in the drug target landscape for autoimmune diseases
1个月前
已完结
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
1个月前
已完结
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
2个月前
已完结
Strategies for targeting cytokines in inflammatory bowel disease
2个月前
已完结
A novel inhalable nanobody targeting IL-4Rα for the treatment of asthma
2个月前
已完结
皖公网安备34019202002308
